CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G. Till, Oliver W. Press, Ajay K. Gopal et al.|Blood|2012Cited by 530
UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMAS.Z. Usmani, Sundar Jagannath, J. G. Berdeja et al.|Hematology Transfusion and Cell Therapy|2021Cited by 21